Copertina

Editorial: Disentangling Early‐Life Antibiotics and Infections as Risk Factors for the Development of Childhood IBD

Fuente: Wiley Open Access

Salvato in:

Dettagli Bibliografici
Autori principali:	Katherine L. Stone, Adam S. Faye
Natura:	Artículo Open Access
Pubblicazione:	Wiley 2024
Soggetti:	Alimentary Pharmacology & Therapeutics
Accesso online:	Acceder al recurso
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi

Letter: The Hidden Truth of IBD Risk—From Antibiotics to Environmental Factors
di: Xueneng Yang, et al.
Pubblicazione: (2025)

Early‐Life Infections, Antibiotics and Later Risk of Childhood and Early Adult‐Onset Inflammatory Bowel Disease: Pooled Analysis of Two Scandinavian Birth Cohorts
di: Karl Mårild, et al.
Pubblicazione: (2024)

Treatment‐Free Outcomes Following Surgery for IBD : A Nationwide Cohort Study
di: Adam S. Faye, et al.
Pubblicazione: (2025)

Editorial: Inflammation and Not Glucocorticoid Therapy is the Key Driver of Fracture Risk in IBD
di: Darcy Quinn Holt, et al.
Pubblicazione: (2024)

Editorial: Shingles Risk in IBD —More Evidence to Support Routine Preventive Vaccination?
di: Keith Bodger
Pubblicazione: (2025)

Editorial: Time to address quality of life in our IBD treatment—IBD nurse intervention as a key part of multimodal IBD management
di: Jakob B. Seidelin
Pubblicazione: (2024)

Editorial: Getting to the Heart of the Matter in IBD
di: Ashwin N. Ananthakrishnan
Pubblicazione: (2025)

Editorial: Remission Ambition—How Far Should We Push in Older Adults? Authors' Reply
di: Catherine Z. Tang, et al.
Pubblicazione: (2025)

Editorial: Updated COVID‐19 Boosters—Tailoring Protection for Patients With IBD
di: James L. Alexander, et al.
Pubblicazione: (2024)

Letter: Geographic Transportability of Shingles Risk With Advanced IBD Therapies
di: Guofu Mao, et al.
Pubblicazione: (2026)

Editorial: Getting to the Heart of the Matter in IBD—Authors' Reply
di: Ramin Ebrahimi, et al.
Pubblicazione: (2025)

Editorial: Targeting Urgency in IBD —A Historical Divide
di: Daniele Noviello, et al.
Pubblicazione: (2025)

Editorial: PSC as an Independent Risk Factor for CRC Without IBD : Can Observed Epidemiological Trends Help Uncover Biological Mechanisms and Guide Surveillance Strategies?
di: Natassia Tan, et al.
Pubblicazione: (2025)

Letter: Diet to Modify Risk of IBD—More Plants and Less Processed Food?
di: Alice S. Day, et al.
Pubblicazione: (2025)

Editorial: Targeting Urgency in IBD —A Historical Divide. Authors' Reply
di: Parul Tandon, et al.
Pubblicazione: (2025)

Editorial: Redefining Safety in Post‐Liver Transplant IBD —Why Therapeutic Effectiveness Is the Ultimate Shield. Authors' Reply
di: Simone Chin, et al.
Pubblicazione: (2025)

Editorial: Toward Safer Pain Management in IBD—Lessons From Prescription Patterns
di: Shabari Shenoy, et al.
Pubblicazione: (2025)

Editorial: Advanced glycation end products ‐ a dietary culprit for IBD in the genetically susceptible?
di: Fahim Ebrahimi, et al.
Pubblicazione: (2024)

Editorial: Toward Safer Pain Management in IBD—Lessons From Prescription Patterns. Authors' Reply
di: Samantha Baillie, et al.
Pubblicazione: (2025)

Primary Sclerosing Cholangitis in the Absence of Inflammatory Bowel Disease Increases the Risk of Colorectal Cancer: A Multi‐Centre Propensity Score Matched Analysis
di: Saqr Alsakarneh, et al.
Pubblicazione: (2025)

Letter: Addressing opioid exposure and associated harms in patients with IBD
di: Christian P. Selinger, et al.
Pubblicazione: (2024)

Letter: H. pylori Infection May Constitute a Risk Factor for Reflux Disease and Colonic Neoplasia
di: Jannis Kountouras, et al.
Pubblicazione: (2025)

Editorial: Association of Antibiotic Exposure With Microscopic Colitis—Authors' Reply
di: Máté Szilcz, et al.
Pubblicazione: (2025)

Review Article: Green Management of IBD—New Paradigms for an Eco‐Friendly Approach
di: Giovanni Cammarota, et al.
Pubblicazione: (2024)

Faecal biomarkers for diagnosis and prediction of disease course in treatment‐naïve patients with IBD
di: Maria Ling Lundström, et al.
Pubblicazione: (2024)

Letter: Differences in Disease Characteristics and Treatment Exposures Between Paediatric and Adult‐Onset IBD
di: Xinli Chen, et al.
Pubblicazione: (2024)

The Effectiveness of Medical Therapies for Joint, Skin and Eye Extraintestinal Manifestations in IBD—An Umbrella Review
di: Olga M. Nardone, et al.
Pubblicazione: (2025)

Review Article: TL1A Inhibitors in IBD ‐ Mechanistic Rationale and Clinical Evidence
di: Manjeet Kumar Goyal, et al.
Pubblicazione: (2026)

Letter: Unlocking the Full Potential of Dietary Therapy in IBD —The Case for Universal Eating Disorder Screening
di: Luisa Bertin, et al.
Pubblicazione: (2026)

Letter: Are Antispasmodics Truly Ineffective in IBD? Considerations on Nuanced Interpretation and Stratified Analysis. Authors' Reply
di: Chachrit Khunsriraksakul, et al.
Pubblicazione: (2025)

Real‐Time Assessment of H. pylori Infection to Guide Molecular Antibiotic Resistance Testing: A Combined Endoscopy‐Gastric Juice Analysis Approach
di: Riccardo Vasapolli, et al.
Pubblicazione: (2024)

Letter: Intestinal permeability accounting for ongoing gastrointestinal symptoms following endoscopic remission in IBD—Authors' reply
di: Arta Aliu, et al.
Pubblicazione: (2024)

Letter: Double‐Dose Hepatitis B Vaccination in IBD —A Step Forward in Protecting Immunosuppressed Patients
di: Luisa Bertin, et al.
Pubblicazione: (2026)

Antibiotic Use and Risk of Microscopic Colitis in Older Adults: A Nationwide Self‐Controlled Case Series Study
di: Máté Szilcz, et al.
Pubblicazione: (2025)

Editorial: Risk of Incident Type 2 Diabetes and Prediabetes in Patients With Direct Acting Antiviral‐Induced Cure of Hepatitis C Virus Infection
di: Nobuharu Tamaki, et al.
Pubblicazione: (2025)

The Prevalence and Risk Factors for at‐Risk MASH and Advanced Liver Fibrosis in People With Metabolic Risk Factors in Primary Care
di: Leon A. Adams, et al.
Pubblicazione: (2026)

Editorial: Risk of Incident Type 2 Diabetes and Prediabetes in Patients With Direct Acting Antiviral‐Induced Cure of Hepatitis C Virus Infection—Authors' Reply
di: Yu‐Ping Chang, et al.
Pubblicazione: (2025)

Editorial: Variceal Bleeding in Patients Receiving Atezolizumab–Bevacizumab for Hepatocellular Carcinoma—Don't Ignore the Risk Factors! Authors' Reply
di: Jonggi Choi
Pubblicazione: (2025)

Increased Risk for Liver Disease in Patients With Chronic Hepatitis B Virus Infection and Low‐Level Viraemia
di: Paul Y. Kwo, et al.
Pubblicazione: (2026)

Patient Plasma‐Induced Neutrophil Dysfunction Is Associated With Infection Risk and Mortality in Patients With Acute Decompensation of Cirrhosis
di: Supachaya Sriphoosanaphan, et al.
Pubblicazione: (2025)